Dupilumab-Associated Lymphoid Reactions Require Caution Dupilumab-Associated Lymphoid Reactions Require Caution
Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 30, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab
MONDAY, Oct. 30, 2023 -- For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 30, 2023 Category: Pharmaceuticals Source Type: news

Chlormethine Gel for the Treatment of Mycosis Fungoides Chlormethine Gel for the Treatment of Mycosis Fungoides
Review the use of chlormethine gel, a topical antineoplastic agent, for the treatment of stage IA and IB mycosis fungoides-cutaneous T-cell lymphoma.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas
(MedPage Today) -- Allogeneic hematopoietic stem cell transplantation (HSCT) was associated with significant improvements in progression-free survival (PFS) in patients with advanced cutaneous T-cell lymphomas (CTCLs), according to the propensity... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 11, 2023 Category: Dermatology Source Type: news

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ... Biopharmaceuticals, Oncology Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2023 Category: Pharmaceuticals Source Type: news

Soligenix Provides Regulatory Update on HyBryte(TM)
PRINCETON, N.J., April 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where ... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin sodium, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 14, 2023 Category: Pharmaceuticals Source Type: news

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Soligenix intends to seek guidance from the FDA on how to further advance HyBryte¬ô towards potential approval PRINCETON, N.J., Feb. 14, 2023 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-... Biopharmaceuticals, Oncology, FDA Soligenix, HyBryte, synthetic hypericin, photodynamic therapy, CTCL (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2023 Category: Pharmaceuticals Source Type: news

Extracorporeal Photopheresis and Its Use in Dermatology Extracorporeal Photopheresis and Its Use in Dermatology
While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 18, 2023 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

New PDT Therapy for CTCL to Be Reviewed by FDA New PDT Therapy for CTCL to Be Reviewed by FDA
The treatment employs an ointment formulation of synthetic hypericin that is preferentially absorbed into malignant cells and activated with visible light, rather than ultraviolet light.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2022 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Pandemic Delayed Treatment in Patients With CTCL, Study Finds Pandemic Delayed Treatment in Patients With CTCL, Study Finds
The retrospective study analyzed data on 149 patients with CTCL who were being managed at one of nine international academic medical centers in seven countries from March through October 2020.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 5, 2022 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

Incidence of Cutaneous T - Cell Lymphoma Up in the U.S.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2022 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Incidence of Cutaneous T-Cell Lymphoma Up in the U.S.
TUESDAY, Sept. 13, 2022 -- The overall incidence of cutaneous T-cell lymphoma (CTCL) increased in the United States from 2000 to 2018, according to a research letter published online Sept. 1 in JAMA Oncology. Zhuo Ran Cai, M.D., from Stanford... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2022 Category: Pharmaceuticals Source Type: news

Michael Girardi appointed Evans Professor of Dermatology
Girardi is an internationally recognized investigator and translational expert in the advancement of personalized therapy for cutaneous T cell lymphoma. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 21, 2022 Category: Universities & Medical Training Source Type: news

Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777
Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the cutaneous T-cell lymphoma indication approval and up to $70 million for additional indication approvals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2021 Category: Pharmaceuticals Source Type: news

Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics
Results are consistent with prior studies that have found Black and Hispanic patients have earlier and more severe disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news